What This Means
This research suggests that a specific gut bacterium called Dubosiella newyorkensis (Dn) can help treat hyperuricemia—a condition where uric acid builds up in the blood, which is the main cause of gout. The researchers discovered this bacterium by using antibiotics to selectively eliminate certain gut bacteria in mice and observing the effects on uric acid levels. They found that Dn works through multiple mechanisms: it lowers uric acid production, helps the kidneys excrete more uric acid by adjusting the activity of key transport proteins (reducing URAT1, which retains uric acid, and increasing ABCG2, which expels it), and also shifts the gut bacterial community toward a healthier balance with more beneficial bacteria and fewer harmful ones.
The beneficial changes in gut bacteria driven by Dn also led to increased production of short-chain fatty acids—particularly acetate, propionate, and butyrate—which are compounds known to support gut and metabolic health. Additionally, Dn treatment reversed kidney damage seen in hyperuricemic mice, including abnormalities in kidney structure such as shrunken filtering units, dilated tubules, and excess collagen buildup, while also reducing oxidative stress and improving overall kidney function markers.
This research suggests that targeting the gut microbiome, specifically by introducing or promoting Dubosiella newyorkensis, could be a promising new strategy for managing hyperuricemia and potentially gout. Unlike single-target drug treatments, Dn appears to address the condition from multiple angles simultaneously—affecting uric acid metabolism, kidney function, and gut health—laying groundwork for future development of microbiome-based therapies for this common metabolic disorder.